Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico, he also explains how the Italian company successfully entered the Mexican market and continues to increase its market share in Mexico, while Menarini further demonstrates its strong commitment to the country by developing and manufacturing specific treatments for the Mexican market.
You were recently elected President of AMIIF for the period 2016-2017. What are the key areas of interest the association will focus on during your tenure?
In order to comply with our economic objectives, AMIIF started to concentrate its efforts on two main missions: advocating for the improvement of our country’s health outcomes in order to further bolster Mexico’s productivity, and attracting more clinical research investments to Mexico.
